Emory University
Radiation Oncology residency · Atlanta, GA · Program website
This program's roster hasn't been collected yet, so there's no list of its own faculty and papers. Below is Emory University's research in radiation oncology, which the program shares with other departments and affiliated hospitals.
About Emory Universityinstitution-wide radiation oncology research
Radiation Oncology publications from Emory University and affiliated institutions, since 2022. Updated 2026-11-06; refreshed daily.
474
works per year
7th of 47 radiation oncology residency programs
+6.2%
2-year growth
34th of 47 radiation oncology residency programs
21.2%
in top 10% of field (works before 2025)
26th of 47 radiation oncology residency programs
44.5%
cited above world average
20th of 47 radiation oncology residency programs
Works per year · * 2026 so far
Oncology · 1,483Radiology, Nuclear Medicine and Imaging · 876
Radiation Oncology research topics at Emory University
Papers in the window; each links to the list on OpenAlex.
- Cancer Immunotherapy and Biomarkers 244
- Cardiac Imaging and Diagnostics 165
- CAR-T cell therapy research 153
- Pancreatic and Hepatic Oncology Research 132
- Advanced MRI Techniques and Applications 120
- Cancer survivorship and care 119
- Global Cancer Incidence and Screening 89
- Radiology practices and education 89
Most cited at Emory University since 2024
All radiation oncology papers there on OpenAlex
- The global, regional, and national burden of cancer, 1990–2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023Lisa M Force et al. · The Lancet · 2025 · PubMed · cited 498
- Management of Fatigue in Adult Survivors of Cancer: ASCO–Society for Integrative Oncology Guideline UpdateJulienne E. Bower et al. · Journal of Clinical Oncology · 2024 · PubMed · cited 317
- CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2018–2022Mackenzie Price et al. · Neuro-Oncology · 2025 · PubMed · cited 227
- Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01Aditya Bardia et al. · Journal of Clinical Oncology · 2024 · PubMed · cited 224
- Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective studyMike Machaba Sathekge et al. · The Lancet Oncology · 2024 · PubMed · cited 216
- First-Line Camizestrant for Emerging ESR1 -Mutated Advanced Breast CancerFrançois‐Clément Bidard et al. · New England Journal of Medicine · 2025 · PubMed · cited 212
- Unanswered questions following reports of secondary malignancies after CAR-T cell therapyBruce L. Levine et al. · Nature Medicine · 2024 · PubMed · cited 205
- Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trialStephen Joseph Bagley et al. · Nature Cancer · 2024 · PubMed · cited 200
- ONC201 (Dordaviprone) in Recurrent H3 K27M–Mutant Diffuse Midline GliomaIsabel Arrillaga‐Romany et al. · Journal of Clinical Oncology · 2024 · PubMed · cited 126
- Epidemiology of Neuroendocrine Neoplasms in the USArvind N. Dasari et al. · JAMA Network Open · 2025 · PubMed · cited 123